CymaBay shares soar on trial update; Lonza opens massive Texas facility dedicated to cell, gene therapies; Inovio lines up $56M
→ Swiss drug manufacturer Lonza wants to cash in on the rising demand for cell and gene therapies, and it reckons Texas is the place …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
